NASDAQ:AUPH
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.'s revenue grew 20.4% in fiscal 2025 to $283.1M while operating margin rose to 37.1%, its highest in 8 years. The diluted share count fell 5.1%.Summary generated from Aurinia Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$283.1M
Revenue growth+20.4%
Revenue, 5-yr CAGR+41.4%
Gross margin88.5%
Operating margin37.1%
Net margin101.5%
ROICn/a
Return on equity59.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change−5.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 46 | 134 | 176 | 235 | 283 |
| Operating income | −181 | −111 | −92 | −5 | 105 |
| Net income | −181 | −108 | −78 | 6 | 287 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 11, 2026 - 4Insider transaction report
Aug 25, 2026 - 8-KOther events
Aug 19, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026 - 8-KCompletion of an acquisition or disposition
May 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026